vs
ARBOR REALTY TRUST INC（ABR）与再鼎医药（ZLAB）财务数据对比。点击上方公司名可切换其他公司
ARBOR REALTY TRUST INC的季度营收约是再鼎医药的1.0倍（$133.4M vs $127.1M），再鼎医药同比增速更快（17.1% vs -12.1%），过去两年再鼎医药的营收复合增速更高（20.8% vs -8.9%）
Arbor Realty Trust Inc.是总部位于美国的专业房地产投资信托（REIT）企业，主要为多户住宅及商业地产项目提供结构性融资服务，涵盖过渡贷款、机构贷款、夹层融资等品类，服务覆盖美国各地的地产持有者、开发商及房产投资群体。
再鼎医药是一家创新生物制药企业，专注于肿瘤、自身免疫性疾病、感染性疾病等领域创新疗法的研发、生产与商业化，核心市场覆盖大中华区，与全球多家头部生物科技企业合作，为存在未被满足医疗需求的患者提供治疗方案。
ABR vs ZLAB — 直观对比
营收规模更大
ABR
是对方的1.0倍
$127.1M
营收增速更快
ZLAB
高出29.2%
-12.1%
两年增速更快
ZLAB
近两年复合增速
-8.9%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $133.4M | $127.1M |
| 净利润 | — | — |
| 毛利率 | — | 51.0% |
| 营业利润率 | — | -54.6% |
| 净利率 | — | — |
| 营收同比 | -12.1% | 17.1% |
| 净利润同比 | — | — |
| 每股收益（稀释后） | $0.08 | $-0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ABRZLAB
| Q4 25 | $133.4M | $127.1M | ||
| Q3 25 | $112.4M | $115.4M | ||
| Q2 25 | $130.4M | $109.1M | ||
| Q1 25 | $134.2M | $105.7M | ||
| Q4 24 | $151.7M | $108.5M | ||
| Q3 24 | $156.7M | $101.8M | ||
| Q2 24 | $153.1M | $100.1M | ||
| Q1 24 | $160.7M | $87.1M |
净利润ABRZLAB
| Q4 25 | — | — | ||
| Q3 25 | $52.0M | $-36.0M | ||
| Q2 25 | $36.3M | $-40.7M | ||
| Q1 25 | $43.4M | $-48.4M | ||
| Q4 24 | — | — | ||
| Q3 24 | $73.5M | $-41.7M | ||
| Q2 24 | $61.8M | $-80.3M | ||
| Q1 24 | $73.2M | $-53.5M |
毛利率ABRZLAB
| Q4 25 | — | 51.0% | ||
| Q3 25 | — | 59.5% | ||
| Q2 25 | — | 60.6% | ||
| Q1 25 | — | 63.6% | ||
| Q4 24 | — | 61.5% | ||
| Q3 24 | — | 64.1% | ||
| Q2 24 | — | 64.9% | ||
| Q1 24 | — | 61.4% |
营业利润率ABRZLAB
| Q4 25 | — | -54.6% | ||
| Q3 25 | — | -42.3% | ||
| Q2 25 | — | -50.3% | ||
| Q1 25 | — | -53.3% | ||
| Q4 24 | — | -62.6% | ||
| Q3 24 | — | -66.6% | ||
| Q2 24 | — | -76.0% | ||
| Q1 24 | 46.9% | -80.7% |
净利率ABRZLAB
| Q4 25 | — | — | ||
| Q3 25 | 46.3% | -31.2% | ||
| Q2 25 | 27.8% | -37.3% | ||
| Q1 25 | 32.3% | -45.8% | ||
| Q4 24 | — | — | ||
| Q3 24 | 46.9% | -40.9% | ||
| Q2 24 | 40.4% | -80.2% | ||
| Q1 24 | 45.6% | -61.4% |
每股收益（稀释后）ABRZLAB
| Q4 25 | $0.08 | $-0.05 | ||
| Q3 25 | $0.20 | $-0.03 | ||
| Q2 25 | $0.12 | $-0.04 | ||
| Q1 25 | $0.16 | $-0.04 | ||
| Q4 24 | $0.31 | $-0.09 | ||
| Q3 24 | $0.31 | $-0.04 | ||
| Q2 24 | $0.25 | $-0.08 | ||
| Q1 24 | $0.31 | $-0.05 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $482.9M | $689.6M |
| 总债务越低越好 | $11.1B | — |
| 股东权益账面价值 | $3.0B | $715.5M |
| 总资产 | $14.5B | $1.2B |
| 负债/权益比越低杠杆越低 | 3.75× | — |
8季度趋势，按日历期对齐
现金及短期投资ABRZLAB
| Q4 25 | $482.9M | $689.6M | ||
| Q3 25 | $423.4M | $717.2M | ||
| Q2 25 | $255.7M | $732.2M | ||
| Q1 25 | $308.8M | $757.3M | ||
| Q4 24 | $503.8M | $779.7M | ||
| Q3 24 | $687.5M | $616.1M | ||
| Q2 24 | $737.5M | $630.0M | ||
| Q1 24 | $908.0M | $650.8M |
总债务ABRZLAB
| Q4 25 | $11.1B | — | ||
| Q3 25 | $10.4B | — | ||
| Q2 25 | $10.1B | — | ||
| Q1 25 | $9.9B | — | ||
| Q4 24 | $10.0B | — | ||
| Q3 24 | $10.3B | — | ||
| Q2 24 | $10.6B | — | ||
| Q1 24 | $11.4B | — |
股东权益ABRZLAB
| Q4 25 | $3.0B | $715.5M | ||
| Q3 25 | $3.0B | $759.9M | ||
| Q2 25 | $3.0B | $791.7M | ||
| Q1 25 | $3.0B | $810.8M | ||
| Q4 24 | $3.0B | $840.9M | ||
| Q3 24 | $3.0B | $667.7M | ||
| Q2 24 | $3.1B | $704.2M | ||
| Q1 24 | $3.1B | $762.2M |
总资产ABRZLAB
| Q4 25 | $14.5B | $1.2B | ||
| Q3 25 | $13.9B | $1.2B | ||
| Q2 25 | $13.6B | $1.2B | ||
| Q1 25 | $13.4B | $1.2B | ||
| Q4 24 | $13.5B | $1.2B | ||
| Q3 24 | $13.9B | $985.3M | ||
| Q2 24 | $14.2B | $987.4M | ||
| Q1 24 | $15.1B | $988.4M |
负债/权益比ABRZLAB
| Q4 25 | 3.75× | — | ||
| Q3 25 | 3.47× | — | ||
| Q2 25 | 3.40× | — | ||
| Q1 25 | 3.29× | — | ||
| Q4 24 | 3.29× | — | ||
| Q3 24 | 3.40× | — | ||
| Q2 24 | 3.47× | — | ||
| Q1 24 | 3.68× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $372.4M | $-26.0M |
| 自由现金流经营现金流 - 资本支出 | — | $-26.7M |
| 自由现金流率自由现金流/营收 | — | -21.0% |
| 资本支出强度资本支出/营收 | — | 0.5% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $-158.9M |
8季度趋势，按日历期对齐
经营现金流ABRZLAB
| Q4 25 | $372.4M | $-26.0M | ||
| Q3 25 | $178.7M | $-32.0M | ||
| Q2 25 | $60.0M | $-31.0M | ||
| Q1 25 | $150.5M | $-61.7M | ||
| Q4 24 | $461.5M | $-55.8M | ||
| Q3 24 | $85.0M | $-26.8M | ||
| Q2 24 | $69.9M | $-42.2M | ||
| Q1 24 | $260.0M | $-90.1M |
自由现金流ABRZLAB
| Q4 25 | — | $-26.7M | ||
| Q3 25 | — | $-35.0M | ||
| Q2 25 | — | $-33.9M | ||
| Q1 25 | — | $-63.2M | ||
| Q4 24 | — | $-58.4M | ||
| Q3 24 | — | $-28.2M | ||
| Q2 24 | — | $-42.9M | ||
| Q1 24 | — | $-91.1M |
自由现金流率ABRZLAB
| Q4 25 | — | -21.0% | ||
| Q3 25 | — | -30.4% | ||
| Q2 25 | — | -31.1% | ||
| Q1 25 | — | -59.9% | ||
| Q4 24 | — | -53.8% | ||
| Q3 24 | — | -27.7% | ||
| Q2 24 | — | -42.9% | ||
| Q1 24 | — | -104.5% |
资本支出强度ABRZLAB
| Q4 25 | — | 0.5% | ||
| Q3 25 | — | 2.6% | ||
| Q2 25 | — | 2.6% | ||
| Q1 25 | — | 1.5% | ||
| Q4 24 | — | 2.4% | ||
| Q3 24 | — | 1.3% | ||
| Q2 24 | — | 0.7% | ||
| Q1 24 | — | 1.1% |
现金转化率ABRZLAB
| Q4 25 | — | — | ||
| Q3 25 | 3.44× | — | ||
| Q2 25 | 1.65× | — | ||
| Q1 25 | 3.47× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 1.16× | — | ||
| Q2 24 | 1.13× | — | ||
| Q1 24 | 3.55× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ABR
暂无分部数据
ZLAB
| Zejula | $56.0M | 44% |
| Other | $21.9M | 17% |
| Nuzyra | $16.0M | 13% |
| Optune | $11.9M | 9% |
| XACDURO | $10.7M | 8% |
| Qinlock | $9.7M | 8% |
| AUGTYRO | $836.0K | 1% |
